Unity’s restructuring comes along with 36-week results from its phase 2b Aspire trial that weighed its investigational eye treatment UBX1325 against Regeneron’s blockbuster Eylea in patients ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some ...

Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...

Among 41 patients treated with 8-mg aflibercept, five developed mild sterile intraocular inflammation within 1 to 3 days. All cases resolved with treatment and caused no permanent vision loss.

Novartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Eylea, the market leader. The TALON trial ...

PARSIPPANY, N.J. & REYKJAVÍK, Iceland, May 05, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE ...

AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept) 2 mg dose, which binds vascular endothelial growth factors (VEGF), inhibiting the binding and ...

The U.S. FDA has approved SELARSDI™ (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of ...

AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea ® (aflibercept) 2 mg dose, which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation ...